Table 2

SP effect on the incidence of clinical malaria during different periods in Ifakara and Manhiça
Outcome
 Placebo
 SP*
 Protective efficacy
 p




Events
 PYAR
 Rate
 Events
 PYAR
 Rate
 (95% CI)
During 1 month after dose 1







Ifakara
 8
 21.71
 0.37
 1
 22.21
 0.05
 87.8% (2.3;98.5)
 0.012
Manhiça
 13
 47.48
 0.27
 1
 49.97
 0.02
 92.7% (44.2;99.0)
 < 0.001
Combined effect adjusted by study
 21
 69.19
 0.30
 2
 72.18
 0.03
 90.9% (61.0;97.9)
 < 0.001
During 1 month after dose 2








Ifakara
 6
 21.83
 0.27
 0
 22.41
 0.00
 100% (.;100)
 0.004
Manhiça
 23
 47.33
 0.49
 10
 50.27
 0.20
 59.0% (13.8;80.5)
 0.014
From 1 month after dose 2 until dose 3







Ifakara
 32
 100.08
 0.32
 16
 106.04
 0.15
 52.8% (14.0;74.1)
 0.011
Manhiça
 92
 169.09
 0.54
 85
 183.36
 0.46
 14.7% (-14.6;36.5)
 0.292
During 1 month after dose 3







Ifakara
 14
 21.51
 0.65
 2
 22.32
 0.09
 86.2% (39.4;96.9)
 0.001
Manhiça
 32
 46.94
 0.68
 16
 49.82
 0.32
 52.7% (13.9;74.1)
 0.012
During 6 months from 1 month after dose 3







Ifakara
 51
 112.56
 0.45
 37
 120.90
 0.31
 32.2% (-3.5;55.6)
 0.070
Manhiça
 107
 228.31
 0.47
 104
 239.31
 0.43
 7.4% (-21.3;29.3)
 0.578

*Sulphadoxine-pyrimethamine

Menendez et al. Malaria Journal 2007 6:132   doi:10.1186/1475-2875-6-132